RB0272 Utility of cambial meristematic cells (CMCs) for commercial therapeutic protein production of Herceptin and Humira

Project Details

StatusFinished
Effective start/end date1/03/13 → 28/02/18

Funding

  • Non-EU other: £763,999.00